Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Keeping Track: US FDA Accepts Ertugliflozin, Extends Reviews Of Abaloparatide, New Keytruda Claim

Executive Summary

The latest drug development news and highlights from our FDA Performance Tracker.

Advertisement

Related Content

Keeping Track: Xermelo, Odactra, Noctiva Approved; Second Submissions For Avelumab And Deutetrabenazine
Keeping Track: Arymo ER Approved, Parsabiv Returns, Merck Surprises With Keytruda Chemo Combo Submission
Jardiance's Label Expansion Will Change Diabetes Management
Keeping Track: Immuno-Oncologics And Abuse-Deterrent Opioids Take Center Stage (Again); Jardiance CV Claim Approved
Keeping Track: FDA Rejects Mealtime Insulin, Antihistamine; Misses Goal For Another Opioid
Keeping Track: Ilaris Adds Three Rare Disease Claims; Sirukumab Submitted; Exondys 51's Surprising Approval
With VERTIS SITA2 On Board, Merck Eyes Broad Initial Approval For Ertugliflozin
Will Radius Health's Abaloparatide Data Do The Trick In Osteoporosis?
ADA: Diabetes Duo Merck & Pfizer Report Positive PhIII Data For Investigational SGLT-2
AstraZeneca Diabetes Combo Needs More Clinical Data, FDA Says

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS120203

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel